论文部分内容阅读
目的 研究肾脏移植术后高脂血症患者外周血单个核细胞中碱性成纤维细胞生长因子(bFGF)及其受体FGFR2mRNA表达水平及降脂治疗后的改变。方法 肾移植术血脂正常组、血脂增高组及正常对照组各30例,血脂增高组应用辛伐他汀20mg/d进行降脂治疗,于服药后1. 5、3个月复查血脂,同时应用逆转录-多聚合酶链反应方法检测外周血单个核细胞碱性成纤维细胞生长因子及其受体mRNA表达。结果 伴高脂血症的肾移植受者辛伐他汀降脂治疗1. 5个月血脂水及外周血单个核细胞中bFGF及其受体FGFR2mRNA显著高于血脂正常组及对照组,辛伐他汀治疗1. 5个月后血脂水平及bFGF、FGFR2mRNA表达水平显著下降,治疗3个月时进一步下降。结论 伴高脂血症的肾移植受者bFGF及其受体FGFR2mRNA表达水平上调,可能是高脂血症引起动脉硬化、慢性移植肾病的机制之一。辛伐他汀降脂治疗可使碱性成纤维细胞生长因子及其受体的表达下调。
Objective To investigate the expression of basic fibroblast growth factor (bFGF) and its receptor FGFR2 mRNA in peripheral blood mononuclear cells (PBMCs) of patients with hyperlipemia after renal transplantation and the changes after bFGF treatment. Methods Thirty patients in the normal group, 30 cases of hyperlipidemia group and 30 cases of normal control group were enrolled in this study. The patients with hyperlipidemia were treated with simvastatin 20 mg / d for lipid lowering treatment, and the blood lipids were retreated at 1. 5 and 3 months after treatment. Detection of Basic Fibroblast Growth Factor and Its Receptor mRNA Expression in Peripheral Blood Mononuclear Cells by Polymerase Chain Reaction. Results Simvastatin-induced lipid-lowering therapy in renal transplant recipients with hyperlipidemia was associated with a significant increase in bFGF and its receptor FGFR2 mRNA in serum lipids and peripheral blood mononuclear cells Blood lipid levels and the expression of bFGF and FGFR2 mRNA decreased significantly after treatment for 1.5 months and further decreased at 3 months. Conclusion The up-regulation of bFGF and its receptor FGFR2 mRNA expression in renal allograft recipients with hyperlipidemia may be one of the mechanisms of arteriosclerosis and chronic graft-versus-nephropathy caused by hyperlipidemia. Simvastatin lipid-lowering treatment can down-regulate the expression of basic fibroblast growth factor and its receptor.